UniProtKB/Swiss-Prot P51531: Variant p.Arg855Gly

Probable global transcription activator SNF2L2
Gene: SMARCA2
Chromosomal location: 9p22.3
Variant information

Variant position:  855
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Glycine (G) at position 855 (R855G, p.Arg855Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Nicolaides-Baraitser syndrome (NCBRS) [MIM:601358]: A rare disorder characterized by severe mental retardation with absent or limited speech, seizures, short stature, sparse hair, typical facial characteristics, brachydactyly, prominent finger joints and broad distal phalanges. Some of the features are progressive with time. {ECO:0000269|PubMed:22366787, ECO:0000269|PubMed:22426308, ECO:0000269|PubMed:23906836, ECO:0000269|PubMed:27665729}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In NCBRS.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  855
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1590
The length of the canonical sequence.

Location on the sequence:   KDKHILAKIRWKYMIVDEGH  R MKNHHCKLTQVLNTHYVAPR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPR

Mouse                         KDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPR

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1590 Probable global transcription activator SNF2L2
Domain 736 – 901 Helicase ATP-binding


Literature citations

Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome.
Van Houdt J.K.; Nowakowska B.A.; Sousa S.B.; van Schaik B.D.; Seuntjens E.; Avonce N.; Sifrim A.; Abdul-Rahman O.A.; van den Boogaard M.J.; Bottani A.; Castori M.; Cormier-Daire V.; Deardorff M.A.; Filges I.; Fryer A.; Fryns J.P.; Gana S.; Garavelli L.; Gillessen-Kaesbach G.; Hall B.D.; Horn D.; Huylebroeck D.; Klapecki J.; Krajewska-Walasek M.; Kuechler A.; Lines M.A.; Maas S.; Macdermot K.D.; McKee S.; Magee A.; de Man S.A.; Moreau Y.; Morice-Picard F.; Obersztyn E.; Pilch J.; Rosser E.; Shannon N.; Stolte-Dijkstra I.; Van Dijck P.; Vilain C.; Vogels A.; Wakeling E.; Wieczorek D.; Wilson L.; Zuffardi O.; van Kampen A.H.; Devriendt K.; Hennekam R.; Vermeesch J.R.;
Nat. Genet. 44:445-449(2012)
Cited for: VARIANTS NCBRS ALA-752; ARG-755; ILE-756; HIS-851; ASP-852; LYS-852; ARG-854; ASN-854; GLY-855; ARG-881; VAL-881; LEU-883; TYR-939; SER-946; PHE-946; CYS-1105; PRO-1105; PRO-1135; ARG-1146; VAL-1158; GLY-1159; LEU-1159; GLN-1159; HIS-1162; PRO-1188; VAL-1201; CYS-1202; GLY-1205 AND TRP-1213;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.